RNS Number : 0908D
Clinigen Group plc
23 October 2020
23 October 2020
Grant of share options and PDMR notification
Clinigen Group plc
(AIM: CLIN, "Clinigen" or the "Company"), announces that, on 22 October 2020, the following Directors were granted share options over a total of 191,163 ordinary shares of
0.1 pence each ("Ordinary Shares"), granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 22 October 2023 subject to the achievement of certain performance criteria.
|
Director/PDMR
|
Number of share options granted
|
Total number of share options now held
|
|
Total number of ordinary shares now held
|
Total number of ordinary shares (excluding share options) as % issued share capital
|
|
Shaun Chilton
|
127,442
|
645,377
|
|
330,044
|
0.25%
|
|
Nick Keher
|
63,721
|
200,610
|
|
10,100
|
0.01%
|
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name
|
Shaun Chilton
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Group Chief Executive Officer
|
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Clinigen Group plc
|
|
b)
|
Legal Entity Identifier
|
213800OBIKGI2JYYS227
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 0.1 pence each
GB00B89J2419
|
|
b)
|
Nature of the transaction
|
Grant of Options
|
|
c)
|
Currency
|
GBP
|
|
d)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
127,442
|
|
|
|
e)
|
Aggregated information
- Aggregated volume
- Price
- Aggregated total
|
127,442
Nil
|
|
f)
|
Date of the transaction
|
22 October 2020
|
|
g)
|
Place of the transaction
|
London Stock Exchange, AIM
|
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name
|
Nick Keher
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Clinigen Group plc
|
|
b)
|
Legal Entity Identifier
|
213800OBIKGI2JYYS227
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 0.1 pence each
GB00B89J2419
|
|
b)
|
Nature of the transaction
|
Grant of Options
|
|
c)
|
Currency
|
GBP
|
|
d)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
Nil
|
63,721
|
|
|
|
e)
|
Aggregated information
- Aggregated volume
- Price
- Aggregated total
|
63,721
Nil
|
|
f)
|
Date of the transaction
|
22 October 2020
|
|
g)
|
Place of the transaction
|
London Stock Exchange, AIM
|
-Ends-
Contact Details
|
Clinigen Group plc
|
Tel: +44 (0) 1283 495 010
|
|
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
|
|
|
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker
|
Tel: +44 (0) 20 7742 4000
|
|
James Mitford / Hemant Kapoor
|
|
|
|
|
|
RBC Capital Markets - Joint Broker
|
Tel: +44 (0) 20 7653 4000
|
|
Marcus Jackson / Elliot Thomas
|
|
|
|
|
|
Instinctif Partners
|
Tel: +44 (0) 20 7457 2020
|
|
Adrian Duffield / Melanie Toyne-Sewell / Phillip Marriage
|
Email:
clinigen@instinctif.com
|
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and the Asia Pacific region.
Clinigen now has over 1,150 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long term growth regions. The Group works with 21 of the top 25 pharmaceutical companies; interacting with over 18,000 registered users across 115 countries, shipping approximately 6.5 million units in the year.
For more information on Clinigen, please visit
www.clinigengroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
DSHKKNBQBBDDQKB
|
